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Dysglycemia and
Cardiovascular Risk
I read with interest the “state-of-the art” paper by Grundy (1) that
was recently published in the Journal. The paper demonstrated that
the pre-diabetic range of glucose levels do not directly cause
atherosclerosis or its complications, on the basis of a systemic
review of the relationship between pre-diabetes and cardiovascular
disease (CVD). The paper also indicated that the major targets for
the prevention of CVD are elevations of cholesterol and blood
pressure, but not elevations of plasma glucose, because certain
clinical trials have suggested that the glucose-lowering drugs did
not retard atherogenesis. My question is whether it is in fact
reasonable to exclude the clinical worth of lowering glucose,
especially in postprandial hyperglycemia, for the prevention of
CVD in subjects with pre-diabetes.
Both epidemiological and interventional studies have shown
that pre-diabetes, especially in post-prandial hyperglycemia, is a
direct and independent risk factor for CVD (2–4). In the
DECODE (Diabetes Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Asia) study, the risk for CVD and stroke
increased progressively with the change from impaired fasting
glucose to impaired glucose tolerance (IGT) to type 2 diabetes (5),
indicating that hyperglycemia is a risk factor for cardiovascular(CV) mortality. The relation between glycemia and CV risk
started within the normal blood glucose range, with a linear
relationship (4,5). In addition, post-challenge hyperglycemia is
strongly associated with future macrovascular events and total
mortality in patients with acute myocardial infarction and/or
patients with coronary disease who received angiography (6).
The results of the STOP-NIDDM (Study to Prevent Non-
Insulin-Dependent Diabetes Mellitus) trial demonstrated that
treating IGT with acarbose, an alpha-glucosidase inhibitor, which
specifically reduces postprandial hyperglycemia, significantly re-
duces the conversion rate of IGT to type 2 diabetes associated with
reductions in the development of CV events (by 49%), the
incidence of new cases of hypertension (by 34%) (7), and the
annual increase of carotid intima–media thickness (by 50%) (8).
Moreover, pioglitazone significantly reduces diastolic blood pres-
sure and the rate of the intima–media thickness associated with a
reduction in the conversion of IGT to type 2 diabetes (9).
Thus, dysglycemia, especially in the case of postprandial hyper-
glycemia, is related to CV risk and mortality, and a variety of
pharmacological and nonpharmacological therapies should be
targeted to the management of postprandial blood glucose inde-
pendent of blood pressure and/or cholesterol.
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